Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: New therapeutic strategies

Journal of Leukocyte Biology

Volumn 80, Issue 5, 2006, Pages 1103-1110

  Aquaro, Stefano ^a,b   Svicher, Valentina ^a   Schols, Dominique ^c   Pollicita, Michela ^a   Antinori, Andrea ^d   Balzarini, Jan ^c   Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Anti HIV drugs; CCR5 coreceptor; gp41; Protease; Reverse transcriptase

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; PHOSPHONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

CD4+ T LYMPHOCYTE; CELL SURVIVAL; CYTOPATHOLOGY; DISEASE COURSE; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MACROPHAGE; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW; TARGET CELL; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750478020     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0606376     Document Type: Review

References (101)

1. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853-860.
2. Valenti, W. M. (2001) HAART is cost-effective and improves outcomes. AIDS Read. 11, 260-262.
3. King, J. T., Justice, A. C., Roberts, M. S., Chang, C. C., Fusco, J. S., Collaboration in HIV Outcomes Research-US Program Team. (2003) Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Making 23, 9-20.
4. Williams, K. C., Hickey, W. F. (2002) Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu. Rev. Neurosci. 25, 537-562.
5. Tomkowicz, B., Lee, C., Ravyn, V., Cheung, R., Ptasznik, A., Collman, R. (2006) The Src kinase Lyn is required for CCR5 signaling in response to MIP-1{β} and R5 HIV-1 gp120 in human macrophages. Blood 108, 1145-1150.
6. Herbein, G., Coaquette, A., Perez-Bercoff, D., Pancino, G. (2002) Macrophage activation and HIV infection: can the Trojan horse turn into a fortress? Curr. Mol. Med. 2, 723-738.
7. Crowe, S. M., Mills, J., Kirihara, J., Boothman, J., Marshall, J. A., McGrath, M. S. (1990) Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res. Hum. Retroviruses 6, 1031-1037.
8. Badley, A. D., Dockrell, D., Simpson, M., Schut, R., Lynch, D. H., Leibson, P., Paya, C. V. (1997) Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J. Exp. Med. 185, 55-64.
9. Herbein, G., Mahlknecht, U., Batliwalla, F., Gregersen, P., Pappas, T., Butler, J., O'Brien, W. A., Verdin, E. (1998) Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395, 189-194.
10. Shi, B., De Girolami, U., He, J., Wang, S., Lorenzo, A., Busciglio, J., Gabuzda, D. (1996) Apoptosis induced by HIV-1 infection of the central nervous system. J. Clin. Invest. 98, 1979-1990.
11. Aquaro, S., Panti, S., Caroleo, M. C., Balestra, E., Cenci, A., Forbici, F., Ippolito, G., Mastino, A., Testi, R., Mollace, V., Calio, R., Perno, C. F. (2000) Primary macrophages infected by human immunodeficiency virus trigger CD95-mediated apoptosis of uninfected astrocytes. J. Leukoc. Biol. 68, 429-435.
12. Mollace, V., Salvemini, D., Riley, D. P., Muscoli, C., Iannone, M., Granato, T., Masuelli, L., Modesti, A., Rotiroti, D., Nistico, R., Bertoli, A., Perno, C. F., Aquaro, S. (2002) The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. J. Leukoc. Biol. 71, 65-72.
13. Garaci, E., Aquaro, S., Lapenta, C., Amendola, A., Spada, M., Covaceuszach, S., Perno, C. F., Belardelli, F. (2003) Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD44+ T lymphocytes in hu-SCID mice. Proc. Natl. Acad. Sci. USA 100, 8927-8932.
14. Koenig, S., Gendelman, H. E., Orenstein, J. M., Dal Canto, M. C., Pezeshkpour, G. H., Yungbluth, M., Janotta, F., Aksamit, A., Martin, M. A., Fauci, A. S. (1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 1089-1093.
15. Tschachler, E., Groh, V., Popovic, M., Mann, D. L., Konrad, K., Safai, B., Eron, L., Di Marzo Veronese, F., Wolff, K., Stingl, G. (1987) Epidermal Langerhans cells a target for HTLV-III/LAV infection. J. Invest. Dermatol. 88, 233-237.
16. McElrath, M. J., Pruett, J. E., Cohn, Z. A. (1989) Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc. Natl. Acad. Sci. USA 86, 675-679.
17. Gabuzda, D. H., Ho, D. D., de la Monte, S. M., Hirsch, M. S., Rota, T. R., Sobel, R. A. (1986) Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann. Neurol. 20, 289-295.
18. Giulian, D., Vaca, K., Noonan, C. A. (1990) Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250, 1593-1596.
19. Tyor, W. R., Power, C., Gendelman, H. E., Markham, R. B. (1993) A model of human immunodeficiency virus encephalitis in SCID mice. Proc. Natl. Acad. Sci. USA 90, 8658-8662.
20. Bagnarelli, P., Valenza, A., Menzo, S., Sampaolesi, R., Varaldo, P. E., Butini, L., Montoni, M., Perno, C. F., Aquaro, S., Mathez, D., Leibowitch, J., Balotta, C., Clementi, M. (1996) Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J. Virol. 70, 7603-7613.
21. Gendelman, H. E., Orenstein, J. M., Martin, M. A., Ferrua, C., Mitra, R., Phipps, T., Wahl, L. A., Lane, H. C., Fauci, A. S., Burke, D. S. (1988) Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167, 1428-1441.
22. Orenstein, J. M., Meltzer, M. S., Phipps, T., Gendelman, H. E. (1988) Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J. Virol. 62, 2578-2586.
23. Aquaro, S., Bagnarelli, P., Guenci, T., De Luca, A., Clementi, M., Balestra, E., Caliò, R., Perno, C. F. (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68, 479-488.
24. Garaci, E., Caroleo, M. C., Aloe, L., Aquaro, S., Piacentini, M., Costa, N., Amendola, A., Micera, A., Caliò, R., Perno, C. F. Levi-Montalcini, R. (1999) Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc. Natl. Acad. Sci. USA 96, 14013-10418.
25. De Clercq, E. (2004) Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2, 704-720.
26. Parniak, M. A., Sluis-Cremer, N. (2000) Inhibitors of HIV-1 reverse transcriptase. Acta. Pharmacol. 49, 67-109.
27. Clavel, F., Hance, A. J. (2004) HIV drug resistance. N. Engl. J. Med. 350, 1023-1035.
28. Balzarini, J. (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. 4, 921-944.
29. Perno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Webb, D. S., Hao, Z., Mitsuya, H., Johns, D. G., Broder, S. (1988) Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 168, 1111-1125.
30. Ahluwalia, G., Cooney, D. A., Mitsuya, H., Fridland, A., Flora, K. P., Hao, Z., Dalal, M., Broder, S., Johns, D. G. (1987) Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36, 3797-3801.
31. Balzarini, J., Kang, G. J., Dalal, M., Herdewijn, P., De Clercq, E., Broder, S., Johns, D. G. (1987) The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2′,3′-didehydro-2′,3′- dideoxyribonucleosides: a comparison with their parental 2′,3′- dideoxyribonucleosides. Mol. Pharmacol. 32, 162-167.
32. Balzarini, J., Baba, M., Pauwels, R., Herdewijn, P., De Clercq, E. (1988) Anti-retrovirus activity of 3′-fluoro- and 3′-azidosubstituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 37, 2847-2856.
33. Balzarini, J., Herdewijn, P., De Clercq, E. (1989) Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′- dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264, 6127-6133.
34. Johnson, M. A., Fridland, A. (1989) Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36, 291-295.
35. Hao, Z., Cooney, D. A., Farquhar, D., Perno, C. F., Zhang, K., Masood, R., Wilson, Y., Hartman, N. R., Balzarini, J., Johns, D. G. (1990) Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2′,3′-dideoxyuridine-5′- triphosphate. Mol. Pharmacol. 37, 157-163.
36. Aquaro, S., Perno, C. F., Balestra, E., Balzarini, J., Cenci, A., Francesconi, M., Panti, S., Serra, F., Villani, N., Caliò, R. (1997) Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol. 62, 138-143.
37. Aquaro, S., Caliò, R., Balestra, E., Bagnarelli, P., Cenci, A., Bertoli, A., Tavazzi, B., Di Pierro, D., Francesconi, M., Abdelahad, D., Perno, C. F. (1998) Clinical implications of HIV dynamics and drug resistance in macrophages. J. Biol. Regul. Homeost. Agents 12, 23-27.
38. Malorni, W., Lucia, M. B., Rainaldi, G., Cauda, R., Cianfriglia, M., Donelli, G., Ortona, L. (1998) Intracellular expression of p170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica 83, 13-20.
39. Haworth, S. J., Christofalo, B., Anderson, R. D., Dunkle, L. M. (1998) A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17, 235-238.
40. Lewis, L. L., Venzon, D., Church, J., Farley, M., Wheeler, S., Keller, A., Rubin, M., Yuen, G., Mueller, B., Sloas, M., Wood, L., Balis, F., Shearer, G. M., Brouwers, P., Goldsmith, J., Pizzo, P. A. (1996) Lamivudine in children with human immunodeficiency virus infection: a phase I-II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J. Infect. Dis. 174, 16-25.
41. Limoges, J., Persidsky, Y., Poluektova, L., Rasmussen, J., Ratanasuwan, W., Zelivyanskaya, M., McClernon, D. R., Lanier, E. R., Gendelman, H. E. (2000) Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 54, 379-389.
42. Aquaro, S., Svicher, V., Cenci, A., Ceccherini-Silberstein, F., Marcuccilli, F., Giannella, S., Marcon, L., Caliò, R., Balzarini, J., Perno, C. F. (2005) Limited development and progression of resistance to the nucleoside analogue reverse transcriptase inhibitor 3TC in human primary macrophages. J. Antimicrob. Chemother. 55, 872-878.
43. Cunningham, P. H., Smith, D. G., Satchell, C., Cooper, D. A., Brew, B. (2000) Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14, 1949-1954.
44. Tang, Y. W., Huong, J. T., Lloyd, R. M., Spearman, P., Haas, D. W. (2000) Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma. J. Clin. Microbiol. 38, 4637-4639.
45. Venturi, G., Catucci, M., Romano, L., Corsi, P., Leoncini, F., Valensin, P. E., Zazzi, M. (2000) Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J. Infect. Dis. 181, 740-745.
46. Price, R. W., Palmatier, R., Wring, S., Lu, J., Baker, B., Sailstad, J., Lollo, N., Spudich, S., Hoh, R., Liegler, T., Miralles, D., Kuritzkes, D., Deeks, S. (2005) Enfuvirtide cerebrospinal fluid pharmacokinetics: a potential tool to analyze CSF HIV origin and the therapeutic role of local drug penetration. 12th Conf. Retrovir. Opportunistic Infect. a402.
47. Bestetti, A., Presi, S., Pierotti, C., Bossolasco, S., Sala, S., Racca, S., Carrera, P., Lazzarin, A., Cinque, P. (2004) Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J. Neurovirol. 10 (Suppl. 1), 52-57.
48. Boyer, P. L., Hughes, S. H. (1995) Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39, 1624-1628.
49. Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., Van Kuilenburg, A. B., Van Gennip, A. H., Berkhout, B. (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15, 4040-4049.
50. Sharma, P. L., Crumpacker, C. S. (1999) Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J. Virol. 73, 8448-8456.
51. Huang, H., Chopra, R., Verdine, G. L., Harrison, S. C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-1675.
52. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rasemberg, I., Holy, A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8, 261-272.
53. Balzarini, J., Aquaro, S., Perno, C. F., Witvrouw, M., Holy, A., De Clercq, E. (1996) Activity of the (R)-enantiomers of 9-(2- phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxypropyl)-2-6- diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219, 337-341.
54. Perno, C. F., Svicher, V., Schols, D., Pollicita, M., Balzarini, J., Aquaro, S. (2006) Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res. 71, 293-300.
55. Perno, C. F., Aquaro, S., Rosenwirth, B., Balestra, E., Peichl, P., Billich, A., Villani, N., Caliò, R. (1994) In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J. Leukoc. Biol. 56, 381-386.
56. Perno, C. F., Newcomb, F. M., Davis, D. A., Aquaro, S., Humphrey, R. W., Caliò, R., Yarchoan, R. (1998) Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 178, 413-422.
57. Ketas, T. J., Frank, I., Klasse, P. J., Sullivan, B. M., Gardner, J. P., Spenlehauer, C., Nesin, M., Olson, W. C., Moore, J. P., Pope, M. (2003) Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J. Virol. 77, 2762-2767.
58. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905.
59. Strizki, J. M., Tremblay, C., Xu, S., Wojcik, L., Wagner, N., Gonsiorek, W., Hipkin, R. W., Chou, C. C., Pugliese-Sivo, C., Xiao, Y., Tagat, J. R., Cox, K., Priestley, T., Sorota, S., Huang, W., Hirsch, M., Reyes, G. R., Baroudy, B. M. (2005) Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49, 4911-4919.
60. Walker, D. K., Abel, S., Comby, P., Muirhead, G. J., Nedderman, A. N., Smith D. A. (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab. Dispos. 33, 587-595.
61. De Clercq, E., Holy, A., Rosemberg, I., Sakuma, T., Balzarini, J., Maudgal, P. C. (1986) A novel selective broad-spectrumanti-DNA agent. Nature 323, 464-467.
62. Balzarini, J., Van Herrewege, Y., Vanham, G. (2002) Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 16, 2159-2163.
63. Andries, K., Azijn, H., Thielemans, T., Ludovici, D., Kukla, M., Heeres, J., Janssen, P., De Corte, B., Vingerhoets, J., Pauwels, R., de Bethune, M. P. (2004) TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48, 4680-4686.
64. Fattorusso, C., Gemma, S., Butini, S., Huleatt, P., Catalanotti, B., Persico, M., De Angelis, M., Fiorini, I., Nacci, V., Ramunno, A., Rodriquez, M., Greco, G., Novellino, E., Bergamini, A., Marini, S., Coletta, M., Maga, G., Spadari, S., Campiani, G. (2005) Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. J. Med. Chem. 48, 7153-7165.
65. Perno, C. F., Bergamini, A., Pesce, C. D., Milanese, G., Capozzi, M., Aquaro, S., Thaisrivongs, S., Tarpley, W. G., Zon, G., D'Agostini, C., Rocchi, G., Garaci, E., Caliò, R. (1993) Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J. Infect. Dis. 168, 1148-1156.
66. De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, P., de Bethune, M. P. (2005) TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49, 2314-2321.
67. Aquaro, S., Guenci, T., Di Santo, F., Francesconi, M., Caliò, R., Perno, C. F. (2004) Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus. Antiviral Res. 61, 133-137.
68. Aquaro, S., Bagnarelli, P., Guenci, T., De Luca, A., Clementi, M., Balestra, E., Caliò, R., Perno, C. F. (2002) Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 68, 479-488.
69. Ortiz, G. M., Wellons, M., Brancato, J., Vo, H. T., Zinn, R. L., Clarkson, D. E., Van Loon, K., Bonhoeffer, S., Miralles, G. D., Montefiori, D., Bartlett, J. A., Nixon, D. F. (2001) Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc. Natl. Acad. Sci. USA 98, 13288-13293.
70. Lori, F., Lisziewicz, J. (2001) Structured treatment interruptions for the management of HIV infection. JAMA 286, 2981-2987.
71. Zhou, H., Pandak, W. M., Lyall, V., Natarajan, R., Hylemon, P. B. (2005) HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol. Pharmacol. 68, 690-700.
72. Dressman, J., Kincer, J., Matveev, S. V., Guo, L., Greenberg, R. N., Guerin, T., Meade, D., Li, X. A., Zhu, W., Uittenbogaard, A., Wilson, M. E., Smart, E. J. (2003) HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest. 111, 389-397.
73. Reeves, J. D., Gallo, S. A., Ahmad, N., Miamidian, J., Harvey, P. E., Sharron, M., Pöhlmann, S., Sfakianos, J. N., Derdeyn, C. A., Blumenthal, R., Hunter, E., Doms, R. W. (2002) Sensivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. USA 99, 16249-16254.
74. Mink, M., Greenberg, M. L., Mosier, S. (2002) Impact of HIV-1 gp41 amino acid substitutions (position 36-45) on susceptibility to T20 (Enfuvirtide) in vitro; analysis of primary virus isolates recovered from patients during chronic Enfuvirtide treatment and site-directed mutants in NL4-3. Antivir. Ther. 7, 17-18.
75. Greenberg, M., Cammack, N., Salgo, M., Smiley, L. (2004) HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol. 14, 321-337.
76. Miller, M. D., Hazuda, D. J. (2004) HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resist. Updat. 7, 89-95.
77. Reeves, J. D., Lee, F. H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., Doms, R. W. (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79, 4991-4999.
78. Aquaro, S., Svicher, V., D'Arrigo, R., Visco-Comandini, U., Antinori, A., Santoro, M., Di Perri, G., Lo Caputo, S., Narciso, P., Perno, C. F. (2006) Characterization of Gp41 evolution in a large cohort of HIV-1-infected patients receiving long-term T-20 treatment as a single active drug. 13th Conference on Retroviruses and Opportunistic Infection, Denver, CO, February 5-8.
79. Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., Berger, E. A. (1996) CCCKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958.
80. Weissman, D., Rabin, R. L., Arthos, J., Rubbert, A., Dybul, M., Swofford, R., Venkatesan, S., Farber, J. M., Fauci, A. S. (1997) Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389, 981-985.
81. Tuttle, D. L., Harrison, J. K., Anders, C., Sleasman, J. W., Goodenow, M. M. (1998) Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 72, 4962-4969.
82. Becker, Y. (2005) The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals-a review, hypothesis and implications. Virus Genes 31, 113-119.
83. Glass, W. G., McDermott, D. H., Lim, J. K., Lekhong, S., Yu, S. F., Frank, W. A., Pape, J., Cheshier, R. C., Murphy, P. M. (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40.
84. Goulding, C., McManus, R., Murphy, A., MacDonald, G., Barrett, S., Crowe, J., Hegarty, J., McKiernan, S., Kelleher, D. (2005) The CCR5-Δ32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 54, 1157-1161.
85. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macatney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., Perros, M. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732.
86. Reeves, J. D., Piefer, A. J. (2005) Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766.
87. Westby, M., Van der Ryst, E. (2005) CCR5 antagonists: host-targeted antivirals fort he treatment of HIV infection. Antivir. Chem. Chemother. 16, 339-354.
88. Willey, S., Peters, P. J., Sullivan, W. M., Dorr, P., Perros, M., Clapham, P. R. (2005) Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 68, 96-108.
89. Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M., Van der Ryst, E. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80, 4909-4920.
90. Baritaki, S., Dittmar, M. T., Spandidos, D. A., Krambovitis, E. (2005) In vitro inhibition of R5 HIV-1 infectivity by X4 V3-derived synthetic peptides. Int. J. Mol. Med. 16, 333-336.
91. Ruff, M. R., Polianova, M., Yang, Q. E., Leoung, G. S., Ruscetti, F. W., Pert, C. B. (2003) Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr. HIV Res. 1, 51-67.
92. Ruff, M. R., Melendez-Guerrero, L. M., Yang, Q. E., Ho, W. Z., Mikovits, J. W., Pert, C. B., Ruscetti, F. A. (2001) Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 52, 63-75.
93. Pollicita, M., Ruff, M., Polianova, M., Pert, C., Ranazzi, A., Perno, C. F., Aquaro, S. (2006) Anti-HIV-1 and anti-apoptotic effects of D-ala-peptide T-amide in human macrophages and in a neuronal cell line. 13th Conference on Retroviruses and Opportunistic Infection, Denver, CO, February 5-8.
94. Trkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., Moore, J. P., Maddon, P. J., Olson, W. C. (2001) Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75, 579-588.
95. Chen, X., Yang, L., Zhang, N., Turpin, J. A., Buckheit, R. W., Osterling, C., Oppenheim, J. J., Howard, O. M. (2003) Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 47, 2810-2816.
96. Balzarini, J., Van Laethem, K., Hatse, S., Froeyen, M., Peumans, W., Van Damme, E., Schols, D. (2005) Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120. A new therapeutic concept to hit the Achilles heel of HIV. J. Biol. Chem. 280, 41005-41014.
97. Balzarini, J., Hatse, S., Vermeire, K., Princen, K., Aquaro, S., Perno, C. F., De Clercq, E., Egberink, H., Vanden Mooter, G., Peumans, W., Van Damme, E., Schols, D. (2004) Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 48, 3858-3870.
98. Balzarini, J. (2005) Targeting the glycans of gp120: a novel therapeutic approach aimed at the Achilles heel of HIV. Lancet Infect. Dis. 5, 726-731.
99. Watanabe, N., Nishihara, Y., Yamaguchi, T., Koito, A., Miyoshi, H., Kakeya, H., Osada, H. (2006) Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS Lett. 580, 2598-2602.
100. Ewart, G. D., Nasr, N., Naif, H., Cox, G. B., Cunningham, A. L., Gage, P. W. (2004) Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob. Agents Chemother. 48, 2325-2330.
101. Haffar, O., Dubrovsky, L., Lowe, R., Berro, R., Kashanchi, F., Godden, J., Vanpouille, C., Bajorath, J., Bukrinsky, M. (2005) Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. J. Virol. 79, 13028-13036.